Kura Oncology

Yahoo Finance • 3 days ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venet... Full story

Yahoo Finance • 4 days ago

Kura Oncology to Participate in Upcoming Investor Conference

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that mana... Full story

Yahoo Finance • 12 days ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 development plans to... Full story

Yahoo Finance • 23 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ann... Full story

Yahoo Finance • 25 days ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

September 16event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806... Full story

Yahoo Finance • last month

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that manag... Full story

Yahoo Finance • 2 months ago

Kura Oncology stock price target lowered to $24 at Citizens JMP

Investing.com - Citizens JMP lowered its price target on Kura Oncology (NASDAQ:KURA) to $24.00 from $28.00 on Monday, while maintaining a Market Outperform rating on the stock. The company’s shares, currently trading at $5.54, have decline... Full story

Yahoo Finance • 2 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will re... Full story

Yahoo Finance • 4 months ago

Kura Oncology's SWOT analysis: ziftomenib's potential reshapes AML treatment stock outlook

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company with a market capitalization of $564 million, is making significant strides in the development of precision medicines for cancer treatment. According to Investin... Full story

Yahoo Finance • 4 months ago

Kura Oncology rises after new early-stage trial data for leukemia therapy

[Acute Myeloid Leukemia word, medical term word with medical concepts in whiteboard and medical equipment.] Md Saiful Islam Khan/iStock via Getty Images Shares of Kura Oncology (NASDAQ:KURA [https://seekingalpha.com/symbol/KURA]) gained i... Full story

Yahoo Finance • 5 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its partici... Full story

Yahoo Finance • 6 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its parti... Full story

Yahoo Finance • 6 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in... Full story

Yahoo Finance • 2 years ago

Kura Makes Good On Its $150 Million Infusion And Shoots Up 12%

Kura stock surged to a nearly three-year high Tuesday after Kura Oncology unveiled promising test results for its leukemia treatment. Continue reading... Full story

Yahoo Finance • 2 years ago

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy... Full story

Yahoo Finance • 2 years ago

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Third Quarter 2023 Kura Oncology Inc. Earnings Conference Call. At this time, all lines... Full story

Yahoo Finance • 2 years ago

Kura Oncology Reports Third Quarter 2023 Financial Results

– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftomenib anticipated early in first quarte... Full story

Yahoo Finance • 2 years ago

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, I... Full story

Yahoo Finance • 2 years ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy... Full story

Yahoo Finance • 2 years ago

Kura Oncology to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it wi... Full story